Home > Publications Database > Chenodeoxycholic Acid-Mediated neuroprotection via α-synuclein and BDNF Modulation in MPTP-Induced mouse model of Parkinson's disease. > print

001     277980
005     20250430100241.0
024 7 _ |a 10.1016/j.neuroscience.2025.03.050
|2 doi
024 7 _ |a pmid:40185387
|2 pmid
024 7 _ |a 0306-4522
|2 ISSN
024 7 _ |a 1873-7544
|2 ISSN
037 _ _ |a DZNE-2025-00512
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Mehreen, Mehwish
|b 0
245 _ _ |a Chenodeoxycholic Acid-Mediated neuroprotection via α-synuclein and BDNF Modulation in MPTP-Induced mouse model of Parkinson's disease.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1745917087_9396
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkinson's disease (PD) remains a major challenge in the field of neurodegenerative diseases and requires innovative therapeutic approaches. In this study, we investigated the therapeutic potential of chenodeoxycholic acid (CDCA) in PD using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model. CDCA, a naturally occurring bile acid, has previously shown promise in various neurological disorders by reducing neuronal degeneration and promoting neuronal health, however its utility in PD has not been studied. We divided mice into a control group, an MPTP-induced PD model and a treatment group injected with CDCA. CDCA reduced motor impairment and ameliorated anxiety-like behavior as assessed through the pole and open field test, demonstrated antidepressant effects in the forced swim and tail suspension test, and results of the Y-maze test showed improved cognitive performance. Furthermore, the effective defense against MPTP-induced dopaminergic degeneration was provided by CDCA by improving the morphological and histological features of neurons in the midbrain, hippocampus, cortex and cerebellum. Analysis via RT-PCR revealed that CDCA significantly mitigated MPP + -induced elevations in α-synuclein levels, indicating its potential to preserve neuronal function by modulating synaptic integrity. Additionally, CDCA effectively reduced the associated toxicity by enhancing the low levels of brain-derived neurotrophic factor. Conclusively, given the increasing prevalence of PD and the urgent need for effective neuroprotective strategies, our findings suggest that CDCA exerts neuroprotective effects in an MPTP-induced PD model. These results highlight CDCA as a promising candidate for further investigation in PD therapy and provide a basis for further research into bile acid-based treatments in neurodegenerative diseases.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a BDNF
|2 Other
650 _ 7 |a Chenodeoxycholic acid
|2 Other
650 _ 7 |a MPTP
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a α-synuclein
|2 Other
700 1 _ |a Ali, Mehak
|b 1
700 1 _ |a Tariq, Huraira
|b 2
700 1 _ |a Noor, Aneeqa
|b 3
700 1 _ |a Mumtaz, Sara
|b 4
700 1 _ |a Zafar, Saima
|0 P:(DE-2719)9000358
|b 5
|e Last author
|u dzne
773 _ _ |a 10.1016/j.neuroscience.2025.03.050
|g Vol. 573, p. 442 - 450
|0 PERI:(DE-600)1498423-4
|p 442 - 450
|t Neuroscience
|v 573
|y 2025
|x 0306-4522
856 4 _ |u https://pub.dzne.de/record/277980/files/DZNE-2025-00512%20SUP.zip
856 4 _ |u https://pub.dzne.de/record/277980/files/DZNE-2025-00512.pdf
856 4 _ |u https://pub.dzne.de/record/277980/files/DZNE-2025-00512.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:277980
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9000358
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROSCIENCE : 2022
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-19
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-19
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21